Unicycive Therapeutics (UNCY) EBT (2020 - 2026)

Unicycive Therapeutics (UNCY) has reported EBT for 7 consecutive years, with -$9.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 42.19% year-over-year to -$9.7 million; the trailing twelve-month figure through Jun 2026 stood at -$31.7 million (down 7.83% YoY), and the FY2025 full-year result was -$28.6 million, up 7.6% from the prior year.
• EBT fell to -$9.7 million in Q2 2026 per UNCY's latest filing, from -$8.0 million in the prior quarter.
• Across five years, EBT topped out at -$3.5 million in Q1 2022 and bottomed at -$9.7 million in Q2 2026.
• Historically, EBT has averaged -$6.4 million across 5 years, with a median of -$6.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT plunged 259.82% in 2022, then gained 23.05% in 2025.
• Over 5 years, EBT stood at -$5.3 million in 2022, then retreated by 16.22% to -$6.2 million in 2023, then slumped by 44.82% to -$9.0 million in 2024, then increased by 23.05% to -$6.9 million in 2025, then slumped by 40.57% to -$9.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$9.7 million, -$8.0 million, and -$6.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.